JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

Home
Signaling Pathways

Signaling Pathways

A8219 Gefitinib (ZD1839)
3 Citation

Target: EGFR

Summary: Selective EGFR inhibitor

≥22.34 mg/mL
A2678 SU11274
2 Citation

Target: MET

Summary: C-Met inhibitor,potent and selective

≥28.4 mg/mL
A2942 Masitinib (AB1010)

Target: PDGFR|c-Kit|Lyn

Summary: Tyrosine kinase inhibitor, potent and selective

≥24.95 mg/mL
A8310 PF-562271
1 Citation

Target: FAK|Pyk2

Summary: ATP-competitive FAK inhibitor, reversible

≥25.35 mg/mL
A8320 PF-00562271

Target: FAK|Pyk2

Summary: FAK/Pyk2 inhibitor,potent and ATP-competitive

insoluble in EtOH; insoluble in H2O; ≥11.1 mg/mL
A8325 Tivantinib (ARQ 197)
2 Citation

Target: MET

Summary: C-Met inhibitor,non-ATP-competitive

≥18.47 mg/mL
A8345 PF-562271 HCl

Target: FAK|Pyk2

Summary: FAK/Pyk2 inhibitor

≥26.35 mg/mL
A8476 MK-2461

Target: FLT3|PDGFR|MET|Ron

Summary: C-Met (WT/mutants) inhibitor

≥24.8 mg/mL
B5859 Entrectinib

Target: Trk Receptors|ALK|ROS1

Summary: Orally active inhibitor of ALK kinase

≥28.05 mg/mL
A3433 Gefitinib hydrochloride

Target: EGFR

Summary: Potent EGFR inhibitor

insoluble in EtOH; ≥4.28 mg/mL